ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Arbutus Biopharma Corporation

Arbutus Biopharma Corporation (ABUS)

2.73
-0.05
(-1.80%)
Closed April 18 4:00PM
2.73
0.00
( 0.00% )
Pre Market: 4:00AM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
2.73
Bid
2.70
Ask
3.30
Volume
-
0.00 Day's Range 0.00
1.69 52 Week Range 3.29
Market Cap
Previous Close
2.73
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
1,471,673
Shares Outstanding
179,492,199
Dividend Yield
-
PE Ratio
-6.73
Earnings Per Share (EPS)
-0.41
Revenue
18.14M
Net Profit
-72.85M

About Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid na... Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Burnaby, British Columbia, Can
Founded
1970
Arbutus Biopharma Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ABUS. The last closing price for Arbutus Biopharma was $2.73. Over the last year, Arbutus Biopharma shares have traded in a share price range of $ 1.69 to $ 3.29.

Arbutus Biopharma currently has 179,492,199 shares outstanding. The market capitalization of Arbutus Biopharma is $490.01 million. Arbutus Biopharma has a price to earnings ratio (PE ratio) of -6.73.

ABUS Latest News

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to...

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to...

Arbutus to Participate in Two Upcoming Investor Conferences

WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to...

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Plans to initiate a third Phase 2a clinical...

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.26-8.695652173912.993.032.6913286282.90226441CS
40.187.058823529412.553.292.321286752.94293746CS
120.3414.22594142262.393.292.26514716732.81297388CS
260.9250.82872928181.813.291.6910455462.56540466CS
52-0.21-7.142857142862.943.291.698371792.44593778CS
156-0.31-10.19736842113.046.51.6919387553.4966732CS
260-0.42-13.33333333333.1590.8120645763.66551916CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RWODRedwoods Acquisition Corporation
$ 29.16
(264.65%)
452.88k
ZCMDZhongchao Inc
$ 2.48
(71.03%)
2.08M
WLGSWang and Lee Group Inc
$ 0.702
(40.40%)
304.28k
NUTXNutex Health Inc
$ 0.88
(34.33%)
3.2k
HUBCHub Cyber Security Ltd
$ 1.59
(23.26%)
2.25M
MBOTMicrobot Medical Inc
$ 0.36
(-59.55%)
24
BGLCBioNexus Gene Lab Corporation
$ 0.66
(-22.22%)
29.93k
ISPCiSpecimen Inc
$ 0.3346
(-20.52%)
105.38k
TIRXTian Ruixiang Holdings Ltd
$ 0.6407
(-19.91%)
140.26k
BTCYBiotricity Inc
$ 1.20
(-18.92%)
1.06k
HUBCHub Cyber Security Ltd
$ 1.59
(23.26%)
2.25M
ZCMDZhongchao Inc
$ 2.48
(71.03%)
2.08M
SQQQProShares UltraPro Short QQQ
$ 12.305
(1.95%)
2.05M
SINTSiNtx Technologies Inc
$ 0.0377
(-5.75%)
1.39M
SPCBSuperCom Ltd
$ 0.29
(20.83%)
1.28M

ABUS Discussion

View Posts
Monksdream Monksdream 2 weeks ago
ABUS new 52 hi
πŸ‘οΈ0
db7 db7 2 weeks ago
looking a little better today; i guess it's going to be slow and steady and not the rocket on markman day like i hoped. i think this is looking really good med-long term on the litigation from after that markman ruling

also, looking forward to EASL in june
πŸ‘οΈ0
mick mick 2 weeks ago
ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890
πŸ‘οΈ0
mick mick 2 weeks ago
ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890
πŸ‘οΈ0
mick mick 2 weeks ago
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
πŸ‘οΈ0
mick mick 2 weeks ago
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
πŸ‘οΈ0
mick mick 2 weeks ago
Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
πŸ‘οΈ0
mick mick 2 weeks ago
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
04/04/2024 08:30:49 AM
Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
πŸ‘οΈ0
Paullee Paullee 2 weeks ago
07:15 AM EDT, 04/04/2024 (MT Newswires) -- A US court ruled against Moderna (MRNA) in a patent infringement case by Arbutus (ABUS) over its COVID-19 vaccines, Reuters reported Wednesday.

US District Judge Mitchell Goldberg interpreted the patents in ways that favored Arbutus' case and hurt Moderna', Reuters reported.

Arbutus sued Moderna in 2022, claiming the company's COVID-19 vaccine impinged on its patents for lipid nanoparticles that shield the vaccine's mRNA from the body's immune system.

Moderna and Arbutus did not immediately respond to MT Newswires' requests for comment.
πŸ‘οΈ0
MWM MWM 2 weeks ago
Watching all 3 stocks. $ABUS is kind of moving...
πŸ‘οΈ0
db7 db7 2 weeks ago
was going to take all '3' to explode imo..
πŸ‘οΈ0
MWM MWM 2 weeks ago
Yes, I'm trying to read it myself
πŸ‘οΈ0
db7 db7 2 weeks ago
decision is out; looks like arbutus won '2' and moderna '1' .. please confirm
πŸ‘οΈ0
db7 db7 1 month ago
https://dailycaller.com/2024/03/14/drew-johnson-moderna-covid-vax-patent-infringement-biden-admin/
👍️ 1
Desert dweller Desert dweller 2 months ago
My bad on post a few weeks ago. When I posted about $MRNA cash position, I didn't do the research I should have done and used what was on cash flow statement and didn't look into long term investments, very sloppy of me. Sorry about that.

In today's release, they are projecting to use $4.3 billion of their cash plus investments during 2024. At 12/31/23 they reported cash plus LT investments of $13.3 billion and project about $9 billion at end of 2024. It will take longer than I thought for them to run out of cash and hopefully $ABUS takes a huge chunk of it. Today MRNA had a surprise profit, and I am still hoping that $ABUS finally cleans their clock for their blatant theft of IP.
👍️ 1
Desert dweller Desert dweller 2 months ago
Handle on twitter is @DesertDweller93
πŸ‘οΈ0
MWM MWM 2 months ago
Great post!

What’s your handle on Twitter?
πŸ‘οΈ0
Desert dweller Desert dweller 2 months ago
I've been saying on X for a month or so that $MRNA will be suffering a drop once it becomes known that they have roughly a year's worth of cash left, I just discovered this recently. They are burning almost $7 billion/year and they will report less than that at 12/31/23. That on top of the fact that during the past 3 years, they spent $7 billion in buybacks at prices much higher than current prices, all the way up to $300+. My prediction is major restructuring or significant secondary very soon. I bet they wish they had that cash now instead of overpriced treasury stock but then mgt wouldn't have been able to sell at those inflated covid prices.

Hope $ABUS puts them into bankruptcy, the f'n thieves and I hope ABUS cleans $PFE and Biontech's clock too. They all know they are stealing the tech and just don't care. About time David kicks Goliath's ass again.
πŸ‘οΈ0
MWM MWM 2 months ago
A couple bad headlines for MRNA of late. Here is one of todays...

Moderna’s RSV Vaccine May Lose Efficacy Faster Than GSK and Pfizer’s
πŸ‘οΈ0
db7 db7 2 months ago
yes, quite the drop yesterday and today on mrna... g/l!
πŸ‘οΈ0
MWM MWM 2 months ago
Puts on $MRNA might be the best play. If they have to pay up to $ABUS I have a feeling it might see a precipitous drop...

MRNA bad news is piling up there...
πŸ‘οΈ0
db7 db7 2 months ago
https://twitter.com/themightyforego/status/1755757415750865356?s=46
πŸ‘οΈ0
MWM MWM 2 months ago
And also

Get on Twitter Damn it lol!
πŸ‘οΈ0
db7 db7 2 months ago
wasn't.. will check it out... thanks!!
πŸ‘οΈ0
MWM MWM 2 months ago
Also

Are you watching VKTX?
πŸ‘οΈ0
MWM MWM 2 months ago
Thanks for pointing this out
πŸ‘οΈ0
db7 db7 2 months ago
interesting (although stock isn't reacting): "Watching Arbutus Biopharma; Hearing Jefferies Issues Note On Arbutus Biopharma On LNP Markman Hearing Saying Judge Favors Company Over Moderna. -BENZINGA"
πŸ‘οΈ0
db7 db7 2 months ago
"Markman Hearing set for February 8, 2024 – court will hear arguments on claim construction and expected to issue its order within 60 days of conclusion of the hearing"

from 1/8/2024 Arbutus presentation...
πŸ‘οΈ0
db7 db7 3 months ago
2,000,000 share block trade woke some people up ...........
πŸ‘οΈ0
db7 db7 3 months ago
"With respect to the Moderna lawsuit, fact discovery is currently on-going with the claim construction hearing scheduled for February 8, 2024. According to the Court Scheduling Order, which was issued on March 21, 2023, the court is expected to issue its claim construction order within 60 days of conclusion of the claim construction hearing."

https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-2024-corporate-objectives-and-provides
πŸ‘οΈ0
db7 db7 3 months ago
from what i'm reading, apparently people are not in love with today's update... 1) moderna trial in 2025 when i think it was expected this year and 2) using 'durvalumab' in a trial instead of their own '101' which some say may mean safety signal seen in '101'(?)

all noise to me; markman is why i came here in the first place......

g/l!
πŸ‘οΈ0
db7 db7 3 months ago
with there being several catalysts, it 'possibly' sets up some safety if only 1 goes bad(?)
πŸ‘οΈ0
MWM MWM 3 months ago
I’ll start watching for any unusual options heading into February
πŸ‘οΈ0
db7 db7 3 months ago
ABUS gets 20% of win and then also owns 12%(?) of Genevant as well...
πŸ‘οΈ0
db7 db7 3 months ago
ROIV safer for sure but %-wise ABUS would benefit more......
πŸ‘οΈ0
MWM MWM 3 months ago
$ROIV might be the better play however. Will have to look it up again but I think ROIV would receive the majority of any verdict?
πŸ‘οΈ0
MWM MWM 3 months ago
No, I myself didn’t realize it. Front screen now, thanks db!

When are you going to set up an account on Twitter!!!
πŸ‘οΈ0
db7 db7 3 months ago
yep
πŸ‘οΈ0
db7 db7 3 months ago
correct; pfizer date not yet set 'but' Moderna has... sorry, if I misinterpreted your post...
πŸ‘οΈ0
MWM MWM 3 months ago
I read this wrong. So there are two trails? One against PFE/BNTX and one against MRNA.
Hmmm
πŸ‘οΈ0
MWM MWM 3 months ago
A trial date has not been set, but the trial is expected to commence in the first half of 2025. The lawsuit against Pfizer/BioNTech is ongoing and a date for a claim construction hearing has not been set.
πŸ‘οΈ0
db7 db7 3 months ago
Moderna Claims Construction (ie: Markman hearing) 2/8/2024 with decision expected within 60 days; 'this' should be an event for sure.... positive or negative, we'll have to wait and see- g/l!
πŸ‘οΈ0
MWM MWM 3 months ago
For now, almost all small biotechs have participated in the melt up to close 2023. We will have to see where 2024 takes us. Their biggest catalyst, the lawsuit with MRNA and BNTX is still a ways away.
But it’s one that is always on my radar.
πŸ‘οΈ0
db7 db7 3 months ago
going to be a busy 1st half of the year here...
πŸ‘οΈ0
db7 db7 3 months ago
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-2024-corporate-objectives-and-provides
πŸ‘οΈ0
mick mick 4 months ago
https://www.otcmarkets.com/stock/ABUS
πŸ‘οΈ0
MWM MWM 5 months ago
I’ll be watching thanks
👍️ 1
db7 db7 5 months ago
ABUS ($1.90) 'might' be time to put this one back on radar? https://stocktwits.com/bs010101/message/552178969
πŸ‘οΈ0
db7 db7 5 months ago
Thanks Dew!!
πŸ‘οΈ0
DewDiligence DewDiligence 5 months ago
Lowering HBsAg is the easy part. The question is whether patients who stop treatment will relapse and need to go back on drug; if these patients relapse, then the triple-drug regimen of Imdusiran (AB-729), VTP-300, and a nucleoside is no better than a nucleoside alone.

In other words, it’s too soon to say whether the 3-drug regimen discussed in the ABUS/BRNS* joint PR has any merit.

*f/k/a VACC.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock